What's Happening?
Primadulcine, a new active ingredient derived from primrose, has been introduced by Greenpharma using their in silico platform GAINS/SELNERGY. This ingredient targets the enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD1), which is responsible for cortisol
synthesis, aiming to reduce stress-induced skin aging. Ex vivo studies show Primadulcine increases hyaluronic acid synthesis by 47%, collagen III synthesis by 73%, and restores elastin synthesis by 74% after six days. In vivo tests indicate a significant reduction in wrinkle depth and improvement in skin appearance for most participants. Primadulcine is part of Sweetch's portfolio, emphasizing high-performance, bio-inspired actives that respect the skin ecosystem, particularly for sensitive and stress-prone skin.
Why It's Important?
The introduction of Primadulcine represents a significant advancement in skincare technology, particularly in addressing the effects of chronic stress on skin health. By targeting cortisol synthesis, Primadulcine offers a novel approach to mitigating stress-induced skin aging, which is a growing concern among consumers. The ingredient's ability to enhance key components of skin health, such as hyaluronic acid and collagen, positions it as a valuable addition to the skincare market. As consumers increasingly seek products that offer both efficacy and sustainability, Primadulcine's development aligns with these trends, potentially influencing future innovations in the beauty industry.
